scPharmaceuticals was formed in 2013 to facilitate and advance hospital-equivalent outpatient care through the development of proprietary, effective, and cost-efficient treatment solutions that reduce our healthcare system’s dependence on traditional hospital-based disease management approaches and protocols.

Our lead investigational program, a proprietary, pH-neutral formulation of furosemide, is being developed for subcutaneous administration for the treatment of edema and congestion in patients with heart failure who display a reduced responsiveness to oral diuretics and who do not require hospitalization. As a potential outpatient IV-strength diuretic for heart failure patients with edema, it may effectively treat patients in the comfort of their own homes and reduce overall health-care costs. Our follow-on programs focused on subcutaneous administration of select anti-infective agents are under development to deliver the benefits of convenient at-home treatment, without the IV. 

Through ongoing exploration across a range of therapeutic areas and related treatment paradigms, our goal is to extend the advantages of outpatient care with advanced drug formulations, innovative delivery systems, and other complementary solutions.